Products for license

Treatments

A recombinant human parathyroid hormone that acts as an anti-osteoporosis agent. Used to treat postmenopausal women and to increase bone mass in men with osteoporosis. Also used to treat men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.

A human IgG2 monoclonal antibody (mAb) used to treat postmenopausal osteoporosis, fractures and bone loss in patients undergoing hormone ablation for cancer, as well as inhibition of the progression of bone erosion associated with rheumatoid arthritis.

A human IgG2 mAb that acts as an antineoplastic agent for the prevention of skeletal-related events in patients with bone metastases from multiple myeloma and giant cell tumor of bone.

An Fc-peptide fusion protein for treating adults and pediatrics (1+) with long-term ITP, and for treating aplastic anemia (AA) in adults with inadequate response to conventional therapy.

A human IgG1 mAb for human tumor necrosis factor (TNF). Used to reduce signs and symptoms, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

A chimeric igG1 mAb that acts as an anti-neoplastic agent for treating patients with epidermal growth factor receptor (EGPR)-expressing, RAS wild-type metastatic colorectal cancer and for the treatment of patients with squamous cell cancer of the head and neck.

A recombinant humanized IgG1 mAb used to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer and glioblastoma.

A humanized mAb fragment and a recombinant humanized igG1 isotype designed to bind and inhibit vascular endothelial growth factor (VEGF-A). Used for treating neovascular (Wet) age-related macular degeneration, macular edema following retinal vein occlusion (RVO), and diabetic macular edema.

Treatments

A humanized mAb which acts as an immune checkpoint inhibitor. Targets and blocks PD-1 protein on the surface of T-cells.

A humanized mAb that binds IgE. When overproduced IgE leads to an allergic response, by removing free IgE in the blood, symptoms of an allergic response are reduced.

A humanized mAb that attaches to interleukin-5 receptors on the surface of eosinophils, interfering with binding and activating an immune response.

A humanized mAb that inhibits TNF-a reducing inflammation and other disease symptoms.

A humanized mAb designed to bind alfa-4-beta-7 integrin, a protein found on the surface of certain white blood cells in the gut, reducing inflammation.

A humanized mAb which inhibits IL-17 in the blood. This reduces immune responses and symptoms.

A humanized mAb which acts as an immune checkpoint inhibitor. Targets and blocks PD-1 and PD-L1 proteins on the surface of T-cells.

A humanized mAb that binds to CD38 proteins on the surface of myeloma cells. These cells can then be killed by the immune system.

A humanized mAb that binds ɑ4-integrin present on white blood cells. This prevents autoreactive leukocytes from entering target organs and reduces inflammation.